JP2021512869A5 - - Google Patents

Download PDF

Info

Publication number
JP2021512869A5
JP2021512869A5 JP2020541731A JP2020541731A JP2021512869A5 JP 2021512869 A5 JP2021512869 A5 JP 2021512869A5 JP 2020541731 A JP2020541731 A JP 2020541731A JP 2020541731 A JP2020541731 A JP 2020541731A JP 2021512869 A5 JP2021512869 A5 JP 2021512869A5
Authority
JP
Japan
Prior art keywords
composition
sodium
amount
total weight
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512869A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050076 external-priority patent/WO2019148247A1/en
Publication of JP2021512869A publication Critical patent/JP2021512869A/ja
Publication of JP2021512869A5 publication Critical patent/JP2021512869A5/ja
Pending legal-status Critical Current

Links

JP2020541731A 2018-02-02 2019-02-01 経口製剤及びその使用 Pending JP2021512869A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018900324A AU2018900324A0 (en) 2018-02-02 Oral Formulations and Uses Thereof
AU2018900324 2018-02-02
PCT/AU2019/050076 WO2019148247A1 (en) 2018-02-02 2019-02-01 Oral formulations and uses thereof

Publications (2)

Publication Number Publication Date
JP2021512869A JP2021512869A (ja) 2021-05-20
JP2021512869A5 true JP2021512869A5 (enExample) 2022-01-11

Family

ID=67477795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541731A Pending JP2021512869A (ja) 2018-02-02 2019-02-01 経口製剤及びその使用

Country Status (9)

Country Link
US (1) US20200368166A1 (enExample)
EP (1) EP3746078A4 (enExample)
JP (1) JP2021512869A (enExample)
CN (1) CN111670035A (enExample)
AU (1) AU2019215802A1 (enExample)
CA (1) CA3089656A1 (enExample)
MX (1) MX2020008137A (enExample)
WO (1) WO2019148247A1 (enExample)
ZA (1) ZA202005143B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746077A4 (en) 2018-02-02 2021-10-27 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) PARENTERAL FORMULATIONS AND USES THEREOF
EP3902793A4 (en) * 2018-12-24 2022-09-07 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) MANUFACTURE OF A CHEMICAL COMPOUND, NEW FORM OF SALT, AND ASSOCIATED THERAPEUTIC USES
KR20220050956A (ko) * 2019-08-23 2022-04-25 유스트랄리스 파마슈티칼스 리미티드 (트레이딩 애즈 프레스수라 뉴로) 치료 방법 및 이의 용도
CN118178481A (zh) * 2020-09-30 2024-06-14 杭州远大生物制药有限公司 微生物制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
MX2010000724A (es) * 2007-07-19 2010-06-02 Adelaide Res & Innovation Pty Metodo para reducir presion intracraneal.
US8454993B2 (en) * 2007-11-23 2013-06-04 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
HRP20140759T1 (hr) * 2009-11-18 2014-10-24 Helsinn Healthcare S.A. Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
IN2013MU02031A (enExample) * 2013-06-14 2015-06-05 Novoexcipients Pvt Ltd
HK1221637A1 (zh) * 2013-07-02 2017-06-09 尤斯特拉里斯制药有限公司(以普雷舒拉纽罗作为商号) 用於预防和/或治疗ii型慢性创伤性脑病的方法
DK3068392T5 (da) * 2013-11-12 2021-09-20 Vertex Pharma Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
EP3076953A1 (en) * 2013-12-03 2016-10-12 F. Hoffmann-La Roche AG Pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2021512869A5 (enExample)
JP2015091822A5 (enExample)
TWI583384B (zh) 包含4-胺基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸鹽單水合物之醫藥組合物
JP2021001196A5 (enExample)
JP2011500583A5 (enExample)
JP2018507200A5 (enExample)
JP2016537347A5 (enExample)
JP6301934B2 (ja) チカグレロルを含む固形経口医薬製剤
JP7665702B2 (ja) アキシチニブを含有する医薬組成物
JP2020511419A5 (enExample)
JP2019526591A5 (enExample)
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
US20180064653A1 (en) Pharmaceutical compositions of dimethyl fumarate
US20140010883A1 (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
WO2016079687A1 (en) Oral pharmaceutical composition of teriflunomide
JP7226697B2 (ja) ブロナンセリン含有錠剤
JP2018145095A (ja) エルロチニブ塩酸塩含有医薬組成物
WO2015069203A1 (en) Capsule comprising rupatadine fumarate and montelukast sodium
WO2019171394A1 (en) Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride
CN104093400A (zh) 稳定的无定形雷特格韦钾盐预混料及其制备方法
JP5065519B1 (ja) 結晶性アトルバスタチンカルシウム含有錠剤の製造方法
JP2018184382A (ja) エゼチミブ含有錠剤およびその製法
JPWO2021078835A5 (enExample)
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
TR201720289A2 (tr) Tolperizon Ve Selektif COX-2 İnhibitörü Kombinasyonları